Arcus Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 04:13 pm EDT
Share
Arcus Biosciences, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 9.461 million compared to USD 1.750 million a year ago. Operating loss was USD 76.136 million compared to USD 45.375 million a year ago. Net loss was USD 75.970 million compared to USD 45.074 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 0.93 a year ago. For the half year, total revenue was USD 18.922 million compared to USD 3.500 million a year ago. Operating loss was USD 148.883 million compared to USD 73.775 million a year ago. Net loss was USD 148.563 million compared to USD 72.827 million a year ago. Basic loss per share from continuing operations was USD 2.17 compared to USD 1.57 a year ago.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
ARCUS BIOSCIENCES, INC. 
